Q4 2023

Filed Mar 27, 2024 · 10-K · 87 days after period end · 0000950170-24-036817

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue

$7.04M

derived−33.6% vs Q4 2022

Net Income

-$16.29M

derivedN/M vs Q4 2022

EPS, diluted—

Same quarter

Metric	Q4 2023derived from reported figures	Q4 2022derived from reported figures	Q4 2021derived from reported figures	Q4 2020derived from reported figures
Revenue	$7.04M	$10.60M	$6.34M	$8.85M
Net Income	-$16.29M	-$28.49M	-$22.29M	-$23.45M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR